Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient–Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study

Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer... Oncol Ther (2018) 6:173–187 https://doi.org/10.1007/s40487-018-0087-1 ORIGINAL RESEARCH Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient– Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study . . . Philip Cornford Kieran Jefferson Owen Cole John Gilbody Received: August 6, 2018 / Published online: November 5, 2018 The Author(s) 2018 three centres. The primary outcome measure ABSTRACT was the change in the number of patient–healthcare interactions (patient Introduction: Luteinising hormone-releasing reviews, prostate-specific antigen (PSA) tests, hormone agonist (LHRHa) injections are cur- and LHRHa injections) over a 24-month treat- rently used in the treatment of advanced pros- ment period. tate cancer, but the frequency of injections may Results: This analysis included 47 patients represent a burden to patients and healthcare newly initiated on six-monthly triptorelin and services. The aim of this study was to collect 41 who received 12 months of a one- or three- real-world evidence about clinical and practical monthly LHRHa before switching to six- outcomes for patients with prostate cancer ini- monthly triptorelin. After switching to six- tiating six-monthly triptorelin, or switching monthly triptorelin, there was a statistically from shorter-acting formulations to six- significant reduction in patient reviews (46.8%), monthly triptorelin, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient–Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study

Download PDF
15 pages

Loading next page...
 
/lp/springer-journals/effects-of-initiating-or-switching-to-a-six-monthly-triptorelin-hWR43xxYIo
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-018-0087-1
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2018) 6:173–187 https://doi.org/10.1007/s40487-018-0087-1 ORIGINAL RESEARCH Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient– Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study . . . Philip Cornford Kieran Jefferson Owen Cole John Gilbody Received: August 6, 2018 / Published online: November 5, 2018 The Author(s) 2018 three centres. The primary outcome measure ABSTRACT was the change in the number of patient–healthcare interactions (patient Introduction: Luteinising hormone-releasing reviews, prostate-specific antigen (PSA) tests, hormone agonist (LHRHa) injections are cur- and LHRHa injections) over a 24-month treat- rently used in the treatment of advanced pros- ment period. tate cancer, but the frequency of injections may Results: This analysis included 47 patients represent a burden to patients and healthcare newly initiated on six-monthly triptorelin and services. The aim of this study was to collect 41 who received 12 months of a one- or three- real-world evidence about clinical and practical monthly LHRHa before switching to six- outcomes for patients with prostate cancer ini- monthly triptorelin. After switching to six- tiating six-monthly triptorelin, or switching monthly triptorelin, there was a statistically from shorter-acting formulations to six- significant reduction in patient reviews (46.8%), monthly triptorelin,

Journal

Oncology and Therapy – Springer Journals

Published: Nov 5, 2018

References

  • The economic burden of prostate cancer
    Roehrborn, CG; Black, LK
  • Clinical and economic burden of prostate cancer
    Saunders, R; Plun-Favreau, J; Takizawa, C; Valentine, WJ
  • Economic burden of cancer across the European Union: a population-based cost analysis
    Luengo-Fernandez, R; Leal, J; Gray, A; Sullivan, R
  • Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort
    Crawford, ED; Phillips, JM
  • Triptorelin embonate (6-month formulation)
    Keating, GM
  • Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study
    Lundstrom, EA; Rencken, RK; Wyk, JH
  • Preferred treatment frequency in patients receiving androgen deprivation therapy for advanced prostate cancer
    Fode, M; Nielsen, TK; Al-Hamadani, M; Andersen, JR; Jakobsen, H; Sonksen, J
  • Patient survey exploring preferences in frequency of administration of LHRH agonists
    Khan, A; Davda, R; Dumas, L; Payne, H
  • Assessing the attitudes to prostate cancer treatment among European male patients
    Schulman, C
  • Duration of androgen suppression in the treatment of prostate cancer
    Bolla, M; Reijke, TM; Tienhoven, G
  • Impact of neoadjuvant hormonal therapy on dose-volume histograms in patients with localized prostate cancer under radical radiation therapy
    Samper, PM; Lopez Carrizosa, MC; Perez Casas, A
  • Combined hormonotherapy and definitive radiation therapy in localized prostate adenocarcinoma
    Özyiğit, G; Akyol, F; Önal, C; Sari, S; Gürdalli, S; Yapici, B
  • Quality of life of patients with prostate cancer under androgen deprivation with GnRH analogues: results of the noninterventional study TRIPTOSIX
    Eisenhardt, A; Schneider, T; Scheithe, K; Colling, C; Heidenreich, A; Studiengruppe, T
  • Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation
    Wex, J; Sidhu, M; Odeyemi, I; Abou-Setta, AM; Retsa, P; Tombal, B
  • Selection criteria for initiation and renewal of luteinizing hormone-releasing hormone agonist therapy in patients with prostate cancer: a French prospective observational study
    Lebret, T; Davin, JL; Hennequin, C